Peter Smith
Directeur/Bestuurslid bij RACE ONCOLOGY LIMITED
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Phillip Lynch | M | - | 4 jaar | |
| Borje Andersson | M | - | 4 jaar | |
| Mary Harney | F | - | 3 jaar | |
| Julie Cherrington | M | 66 |
MycRx
 MycRx Miscellaneous Commercial ServicesCommercial Services MycRx is an Australian company that focuses on improving the lives of people with cancer through direct myc inhibitors. The company's main area of expertise is the science of myc inhibition as a treatment for cancer. | 2 jaar |
| Omar Khalil | M | - |
MycRx
MycRx Miscellaneous Commercial ServicesCommercial Services MycRx is an Australian company that focuses on improving the lives of people with cancer through direct myc inhibitors. The company's main area of expertise is the science of myc inhibition as a treatment for cancer. | 3 jaar |
| Peter Webse | M | 61 | - | |
| Daniel Tillett | M | - | 1 jaar | |
| Marinella Messina | M | - | 4 jaar | |
| Christopher Smith | M | - |
MycRx
MycRx Miscellaneous Commercial ServicesCommercial Services MycRx is an Australian company that focuses on improving the lives of people with cancer through direct myc inhibitors. The company's main area of expertise is the science of myc inhibition as a treatment for cancer. | - |
| Stephen Thompson | M | - |
MycRx
MycRx Miscellaneous Commercial ServicesCommercial Services MycRx is an Australian company that focuses on improving the lives of people with cancer through direct myc inhibitors. The company's main area of expertise is the science of myc inhibition as a treatment for cancer. | - |
| Peter Smith | M | - |
MycRx
MycRx Miscellaneous Commercial ServicesCommercial Services MycRx is an Australian company that focuses on improving the lives of people with cancer through direct myc inhibitors. The company's main area of expertise is the science of myc inhibition as a treatment for cancer. | - |
| Alison Thistlethwaite | M | - |
MycRx
MycRx Miscellaneous Commercial ServicesCommercial Services MycRx is an Australian company that focuses on improving the lives of people with cancer through direct myc inhibitors. The company's main area of expertise is the science of myc inhibition as a treatment for cancer. | - |
| Michael Kelso | M | - | 3 jaar | |
| Tim Hammond | M | - | 1 jaar | |
| Sophia Moscovis | M | - | - | |
| Michelle Rashford | M | - | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Charles Walker | M | 53 |
Audeo Oncology, Inc.
 Audeo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Audeo Oncology, Inc. used to provide cancer treatment services. It focused on utilizing its Hyaluronic Acid Chemotransport technology for cancer drugs and tumor cells to enhance drug activities. The company was founded on June 1, 2012 and was headquartered in San Francisco, CA. | 3 jaar |
| Damian Clarke-Bruce | M | - | - | |
| David C. U'Prichard | M | 75 |
Audeo Oncology, Inc.
Audeo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Audeo Oncology, Inc. used to provide cancer treatment services. It focused on utilizing its Hyaluronic Acid Chemotransport technology for cancer drugs and tumor cells to enhance drug activities. The company was founded on June 1, 2012 and was headquartered in San Francisco, CA. | - |
| John Cullity | M | - | 5 jaar | |
| Daniel Sharp | M | - | 1 jaar | |
| Susan Kelley | M | 69 |
Audeo Oncology, Inc.
Audeo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Audeo Oncology, Inc. used to provide cancer treatment services. It focused on utilizing its Hyaluronic Acid Chemotransport technology for cancer drugs and tumor cells to enhance drug activities. The company was founded on June 1, 2012 and was headquartered in San Francisco, CA. | - |
| Kevin Healey | M | 72 | - | |
| Christopher Neal | M | - | - | |
| David Keith Green | M | - | 4 jaar | |
| Stephen Hill | M | 65 |
Audeo Oncology, Inc.
Audeo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Audeo Oncology, Inc. used to provide cancer treatment services. It focused on utilizing its Hyaluronic Acid Chemotransport technology for cancer drugs and tumor cells to enhance drug activities. The company was founded on June 1, 2012 and was headquartered in San Francisco, CA. | - |
| Ajay Duggal | M | - | 1 jaar | |
| Christina Manfre | F | - | 2 jaar | |
| Goslik Schepers | M | - | 5 jaar | |
| Carlo Montagner | M | 56 | 3 jaar | |
| Olaf Brian O'Duill | M | 76 | 2 jaar | |
| Julian Clark | M | - | - | |
| Wim D. F. Meutermans | M | 61 |
Audeo Oncology, Inc.
Audeo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Audeo Oncology, Inc. used to provide cancer treatment services. It focused on utilizing its Hyaluronic Acid Chemotransport technology for cancer drugs and tumor cells to enhance drug activities. The company was founded on June 1, 2012 and was headquartered in San Francisco, CA. | - |
| Kris Dyszynski | M | - | - | |
| Errol Malta | M | - | - | |
| James MacKenzie | M | 70 | 1 jaar | |
| Tracey Brown | M | 61 |
Audeo Oncology, Inc.
Audeo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Audeo Oncology, Inc. used to provide cancer treatment services. It focused on utilizing its Hyaluronic Acid Chemotransport technology for cancer drugs and tumor cells to enhance drug activities. The company was founded on June 1, 2012 and was headquartered in San Francisco, CA. | - |
| Michael West | M | 61 |
Audeo Oncology, Inc.
Audeo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Audeo Oncology, Inc. used to provide cancer treatment services. It focused on utilizing its Hyaluronic Acid Chemotransport technology for cancer drugs and tumor cells to enhance drug activities. The company was founded on June 1, 2012 and was headquartered in San Francisco, CA. | - |
| Tracie Elizabeth Ramsdale | M | 62 |
Audeo Oncology, Inc.
Audeo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Audeo Oncology, Inc. used to provide cancer treatment services. It focused on utilizing its Hyaluronic Acid Chemotransport technology for cancer drugs and tumor cells to enhance drug activities. The company was founded on June 1, 2012 and was headquartered in San Francisco, CA. | - |
| Stephen Denaro | M | - | 5 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Australië | 33 | 82.50% |
| Verenigde Staten | 8 | 20.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Peter Smith
- Persoonlijk netwerk
